Amarin Corp Plc (AMRN)

[dogn]

Eddingpharm activity

Seeing some new updates on Eddingpharm website at https://www.eddingpharm.com/EN/ since last I looked and since they received approval to Launch Vascepa from NMPA in May.

At top under "Our company" they now list
3 Therapeutic Areas ... 6 Core Products ... 16000+ hospitals ... 770+ sales representatives.

And under Our company/history/2023 now show
· The NMPA has [granted] approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL)(VHTG)."

Under "Core Therapeutic Areas" and "Cardiovascular" they note the Reduce-It results and FDA approved CVD indication as well as:
In May 2023, Vascepa® received approval from the NMPA for the treatment of severe HTG levels (≥500 mg/dL). As of June 14, 2023, Vascepa® had already been recommended by seven clinical guidelines in China, including the 2023 China Guidelines for the Management of Blood Lipids.

Under "Full Value Chain"
Vascepa® is a single-molecule product. It is a highly purified omega-3 fatty acid (EPA) ethyl ester.
Vascepa® is the only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in targeted high risk patients. Based on cross trial comparisons, Vascepa® demonstrated significant efficacy advantages over evolocumab (one PCSK-9 inhibitor) and ezetimibe (one cholesterol absorption inhibitor) on top of statin therapy for reducing the risk of cardiovascular events.

We launched Vascepa® in China in 2023.
and an updated Vascepa timeline showing in 2023 NMPA has approved Vascepa for the treatment of severe HTG levels (≥500 mg/dL)

Under Career tab, Talent recruitment learn more link redirects to https://eddingpharm.zhiye.com/Social which using Google chrome translation to English shows a total of 135 job openings, many in "SC" and "CV" areas (presumably supply chain and cardiovascular), majority (over 80-90) posted since May. Looks like they are in growth mode.

dogn